 BALTIMORE--BUSINESS WIRE--MyMD Pharmaceuticals, Inc. Nasdaq: MYMD, a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that the United States Patent and Trademark Office USPTO issued a Notice of Allowance for application no. 16612,472, entitled Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders. The allowed claims cover the new molecular entity Supe 